| The University of Florida Research Foundation, Inc Patent applications |
| Patent application number | Title | Published |
|---|
| 20100196978 | Recombinant Host Cells and Media for Ethanol Production - Disclosed are recombinant host cells suitable for degrading an oligosaccharide that have been optimized for growth and production of high yields of ethanol, and methods of making and using these cells. The invention further provides minimal media comprising urea-like compounds for economical production of ethanol by recombinant microorganisms. Recombinant host cells in accordance with the invention are modified by gene mutation to eliminate genes responsible for the production of unwanted products other than ethanol, thereby increasing the yield of ethanol produced from the oligosaccharides, relative to unmutated parent strains. The new and improved strains of recombinant bacteria are capable of superior ethanol productivity and yield when grown under conditions suitable for fermentation in minimal growth media containing inexpensive reagents. Systems optimized for ethanol production combine a selected optimized minimal medium with a recombinant host cell optimized for use in the selected medium. Preferred systems are suitable for efficient ethanol production by simultaneous saccharification and fermentation (SSF) using lignocellulose as an oligosaccharide source. The invention also provides novel isolated polynucleotide sequences, polypeptide sequences, vectors and antibodies. | 08-05-2010 |
| 20100154565 | MICRO-SCALE OPTICAL FORCE SENSOR INCREASED DYNAMIC RANGE, AND HIGHER SENSITIVITY AND LINEARITY VIA A COMPLIANT LINKAGE, - Exemplary embodiments provide a micro-scale optical force sensor. The device includes a scale grating, a linearly displaceable index grating positioned above and in initial alignment with the scale grating, the index grating aligned with the scale grating absent a force applied to the index grating, and a compliant linkage assembly joined coplanar to the displaceable index grating. The linkage assembly includes at least three rigid support links laterally extending from each of opposing longitudinal edges of the index grating, a displaceable rigid link formed between adjacent support links, and compliant links interposed between a distal end of rigid support links and an inner end of each displaceable rigid link, and interposed between an outer end of rigid support links and the substrate, the compliant links normally biasing the displaceable rigid link parallel to the rigid support links and perpendicular to a longitudinal axis of the index grating. | 06-24-2010 |
| 20090286321 | METHODS FOR TARGETING MODIFIED RAAV VECTORS TO MAMMALIAN CELLS - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells. | 11-19-2009 |
| 20090149414 | rAAV EXPRESSION SYSTEMS AND COMPOSITIONS - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells. | 06-11-2009 |
| 20090148949 | rAAV Expression Systems and Methods of Use - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells. | 06-11-2009 |
| 20090148411 | VIRAL VECTOR-BASED GENE THERAPY METHODS AND COMPOSITIONS - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells. | 06-11-2009 |
| 20090074723 | Method of Treating or Retarding the Development of Blindness - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method. | 03-19-2009 |
